FIG. 1.
HBV‐specific TCR T‐cell therapy of patients with CHB with primary HBV‐HCC did not induce an acute systemic inflammatory reaction. (A) Schematic representation of the infusion protocol. Patients with CHB primary HBV‐HCC (n = 8) were given four infusions of autologous mRNA electroporated HBV‐specific TCR T cells at increasing doses (1 × 104 to 5 × 106 CD8+Vβ+ T cells/Kg) 1 week apart. Subsequent infusions were given with variable number of escalating doses, with a maximum of 5 × 106/kg TCR T cells. (B) CD8+Vβ+ T‐cell frequency of all TCR T‐cell productions were quantified. The frequency before and after HBV‐TCR mRNA electroporation is shown. (C) Systolic and diastolic blood pressure of all treated patients before and 3 days after each infusion. (D) Differential blood counts were performed for all patients during the course of therapy, and markers of systemic inflammation are shown. The shaded regions demarcate the reference ranges of each parameter derived from the mean ± SD observed in healthy individuals.( 16 ) Abbreviation: EP, electroporation.